Published in Ann N Y Acad Sci on September 01, 2003
Myasthenia gravis. Orphanet J Rare Dis (2007) 1.81
Update on myasthenia gravis. Postgrad Med J (2004) 1.00
Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol (2011) 0.90
Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation. Curr Treat Options Neurol (2005) 0.89
An Update on Myasthenic Crisis. Curr Treat Options Neurol (2005) 0.84
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat (2008) 0.82
A crucial first randomized controlled trial of thymectomy in non-thymomatous myasthenia gravis. J Thorac Dis (2016) 0.82
Myasthenia Gravis. Curr Treat Options Neurol (2004) 0.77
Ocular Myasthenia Gravis. Curr Treat Options Neurol (2005) 0.75
Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study. Eur J Med Res (2009) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA (2003) 3.49
White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging (2005) 2.79
A multicenter retrieval study of the taper interfaces of modular hip prostheses. Clin Orthop Relat Res (2002) 2.78
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Association between late-life social activity and motor decline in older adults. Arch Intern Med (2009) 2.26
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Rating scales for dystonia: a multicenter assessment. Mov Disord (2003) 1.77
Self-reported experiences of everyday discrimination are associated with elevated C-reactive protein levels in older African-American adults. Brain Behav Immun (2009) 1.75
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.63
Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology (2008) 1.59
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol (2002) 1.54
Acute stroke care in Illinois: a statewide assessment of diagnostic and treatment capabilities. Stroke (2002) 1.48
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol (2006) 1.47
The localizing yield of sphenoidal and anterior temporal electrodes in ictal recordings: a comparison study. Epilepsia (2002) 1.41
Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA (2012) 1.40
Association of anxiety and depression with microtubule-associated protein 2- and synaptopodin-immunolabeled dendrite and spine densities in hippocampal CA3 of older humans. Arch Gen Psychiatry (2010) 1.27
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol (2002) 1.19
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord (2002) 1.15
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology (2003) 1.12
Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord (2004) 1.05
A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment. Neuroepidemiology (2012) 1.05
The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord (2010) 1.04
Association of total daily physical activity with disability in community-dwelling older persons: a prospective cohort study. BMC Geriatr (2012) 1.04
Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord (2009) 1.01
Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol (2012) 0.97
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol (2004) 0.95
Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol (2012) 0.95
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology (2005) 0.93
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol (2006) 0.92
Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord (2008) 0.92
Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord (2008) 0.92
Broken heart syndrome in myasthenia gravis. Muscle Nerve (2011) 0.91
Is there a link between cancer and Alzheimer disease? Neurology (2009) 0.90
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord (2006) 0.87
Vibratory thresholds and mobility in older persons. Muscle Nerve (2009) 0.87
Disseminated intravascular large-cell lymphoma with initial presentation mimicking Guillain-Barré syndrome. Muscle Nerve (2010) 0.86
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun (2005) 0.86
Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord (2003) 0.85
Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease? Clin Neurophysiol (2008) 0.85
Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord (2005) 0.85
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci (2012) 0.84
Complementary and alternative medicine use in Gilles de la Tourette syndrome. Mov Disord (2009) 0.84
Relation of driving status to incident life space constriction in community-dwelling older persons: a prospective cohort study. J Gerontol A Biol Sci Med Sci (2012) 0.84
The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease. Aging Cell (2011) 0.83
Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol (2003) 0.83
GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity. Neurology (2013) 0.83
Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve (2003) 0.83
Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol (2004) 0.83
Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. Brain Struct Funct (2013) 0.82
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis (2010) 0.82
Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord (2006) 0.81
Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia. J Mot Behav (2008) 0.80
Parkinsonian signs and incident falls in older persons without Parkinson's disease. J Am Geriatr Soc (2010) 0.79
Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord (2008) 0.78
Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol (2003) 0.78
Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord (2006) 0.77
Association of lower hemoglobin level and neuropathology in community-dwelling older persons. J Alzheimers Dis (2012) 0.77
Associations of cerebrovascular and Alzheimer's disease pathology with brain atrophy. Curr Alzheimer Res (2014) 0.77
Resolving kinematic redundancy in target-reaching movements with and without external constraint. Exp Brain Res (2008) 0.77
Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry (2008) 0.76
Transcultural comparison of psychogenic movement disorders. Mov Disord (2005) 0.76
Author response. Neurology (2014) 0.75
Association of cognitive activity and neurocognitive function in blacks and whites with HIV. AIDS (2016) 0.75
Neuroticism modifies the association of vision impairment and cognition among community-dwelling older adults. Neuroepidemiology (2012) 0.75
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol (2009) 0.75
Loneliness in Older Black Adults with Human Immunodeficiency Virus Is Associated with Poorer Cognition. Gerontology (2017) 0.75
Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord (2006) 0.75
Predictors of outcomes after nontraumatic subdural hematoma. J Stroke Cerebrovasc Dis (2007) 0.75